|
|
|
|
|
| The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia |
| Norman E. Lepor1, 2, Laurn Contreras2, Chirag Desai2, Dean J. Kereiakes3 |
1 The David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center, Los Angeles, CA
2 Westside Medical Associates of Los Angeles, Beverly Hills, CA
3 The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH |
|
|
|
Abstract:
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability in developed nations, and it is rising rapidly in other parts of the developing world. Levels of low-density lipoprotein cholesterol (LDL-C) are directly correlated with atherogenic risk, and statin-based therapy is the most common management for these patients. However, many patients exhibit resistance to and/or adverse effects from statin therapy, and there is a need for adjunctive therapies or statin alternatives for these patients. The recently discovered human protein proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in LDL-C metabolism. PCSK9 promotes LDL receptor (LDL-R) degradation with a consequent reduction in LDL-R density and an increase in LDL-C levels. Consequently, PCSK9 inhibition to reduce LDL-C levels has become a primary focus for drug development. Numerous clinical trials focusing on monoclonal antibodies against PCSK9 have demonstrated efficacy equal to or greater than statin therapy for lowering LDL-C levels. Long-term trials are underway to assess safety, tolerability, and ability to reduce ASCVD.
|
|
Published: 30 December 2014
|
| No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
2014, Vol. 15 
